Among patients with high PD‐L1 expression undergoing first‐line pembrolizumab monotherapy for NSCLC, the GPS is significantly correlated with both progression‐free survival and overall survival (OS), and BMI with OS, indicating that they could be used to predict treatment outcome in these patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.